Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A new publication citation has been added under Publications, referencing a Blood Neoplasia article on favezelimab plus pembrolizumab in anti-PD-1-refractory classic Hodgkin lymphoma. This addition provides additional literature context for the study record without altering the study's design, eligibility criteria, or reported results.
    Difference
    0.0%
    Check dated 2026-09-12T23:38:10.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page now includes NIH grant/contract references for 2023 and 2018, indicating funding sources, and the revision history shows an update to Revision: v3.6.6, replacing v3.6.5.
    Difference
    0.1%
    Check dated 2026-08-29T21:48:54.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    37 days ago
    Change Detected
    Summary
    The page now displays a generic error screen indicating the requested record is unavailable, replacing the usual study details with an error notice.
    Difference
    19%
    Check dated 2026-08-08T18:15:00.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The study record shows the status updated to Terminated on 2026-07-28 with a Business Reason indicating no longer looking for participants, replacing the prior Completed status.
    Difference
    0.2%
    Check dated 2026-08-01T14:12:55.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.3 to v3.6.4. This reflects a new entry in the study page's revision history.
    Difference
    0.1%
    Check dated 2026-07-25T10:16:48.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    The study record now indicates completion and recruitment is closed. Enrollment has ended and no new participants will be enrolled.
    Difference
    0.0%
    Check dated 2026-07-18T03:48:11.000Z thumbnail image

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.